Cannprisma Magazine 02/2024

Dear Valued Partners,?

Welcome to Chapter 2 of the Cannprisma Story, where we continue our journey of innovation and growth in the medical cannabis industry.?

?In this edition, we'll explore how we transformed our vision into reality, expanding our capabilities and reaching new heights in quality and production.

Chapter 2: Cultivating Excellence

4. Inauguration of the Cultivation Unit - September 2021

Just a month after obtaining our GACP license, we celebrated a significant milestone with the inauguration of our cultivation unit.

This wasn't just the opening of a new facility, it marked the beginning of a new chapter for Cannprisma.

?

?This state-of-the-art facility, designed with advanced technology, allowed us to optimize growing conditions and ensure the production of high-quality cannabis plants. The controlled environment supported the growth of potent and consistent therapeutic products.

Our team's motivation: Each plant we grew here was a step toward providing relief and hope to patients.??

?Our team was deeply motivated and filled with a sense of purpose, knowing that we could finally start producing the raw materials that bring well-being and comfort to patients. This cultivation unit stood for making a positive difference in patients' lives through quality, consistency, and safety.

5. CUMCS Certification - November 2021?

In November 2021, we reached another significant milestone by obtaining the CUMCS (Control Union Medical Cannabis Standard) certification. This achievement validated our quality control measures and adherence to best practices in cannabis cultivation.

?

CUMCS ensures that medical cannabis is produced under strict quality control measures, from cultivation to post-harvest processing.

The CUMCS certification represented our commitment to producing medical cannabis of the highest quality. It was a collective effort, symbolizing our dedication to continuous improvement and excellence. It reinforced our mission to provide safe, effective, and consistent therapeutic products that patients could rely on.

To quote our CEO & Founder Jo?o Nascimento:?” The CUMCS certification is a game-changer for Cannprisma. It validates our end-to-end approach in medical cannabis production, from sustainable cultivation to rigorous quality control. This seal not only strengthens our position in the European market but also reinforces the trust of patients and healthcare professionals in our products. With CUMCS, we're setting new standards of excellence, ensuring each Cannprisma product is safe, effective, and responsibly produced”

6. Start of the Cultivation Unit Expansion - June 2022

?As the demand for our high-quality products grew, we embarked on the expansion of our cultivation unit in June 2022. This was driven by the increasing European demand for premium cannabis flowers, which highlighted the need to boost our production capacity.

?The additional space allowed us to innovate and refine our cultivation techniques. It enabled us to introduce a wider variety of strains, tailoring our offerings to meet a broader range of clinical conditions?

With this expansion, we aimed to provide a more customized approach to patient care, ensuring that our products could address diverse medical needs.

?By expanding our capacity, we were better equipped to ensure a steady supply of top-tier medical cannabis, helping more patients across Europe find the relief they needed.?

See you in the next chapter ??

We will dig deep into how Cannprisma took the leap from cultivation to full-scale pharmaceutical production. Stay tuned to learn about our journey to obtain EU-GMP certification and how we've positioned ourselves as a Medical Cannabis Hub in the European market.

?We can't wait to share the next part of our story with you!?

Do you Have questions about our journey? We'd love to hear from you!?

?